Daewoong Bio's Hypertension Treatment 'Telmisartan Group' Surpasses 10 Billion Won in Sales After Renewal

TwinBeta bottle packaging. Photo by Daewoong Bio

원본보기 아이콘

Daewoong Bio announced on the 4th that its hypertension treatments, the 'Twinbeta' and 'Telmibeta' series, achieved annual sales of 10 billion KRW last year through a product renewal.

Twinbeta and Telmibeta are hypertension treatments with 'Telmisartan' as the main ingredient. Following last year's renewal, they improved medication convenience by changing from the existing PTP (Press Through Pack) individual packaging to bottle packaging, receiving positive responses in the market. PTP is a packaging method where each dose is individually sealed in a blister made of plastic or aluminum, protruding on one side.

With the renewal last year, the Telmisartan lineup now allows different medications to be included together in a single sachet. This eliminated the hassle of having to open separate PTP packages and enhanced ease of use. Until now, elderly patients or those taking multiple medications for hypertension experienced inconvenience in having to separate and take each medication individually.

The renewed products overcame the previous formulation’s issue that required individual packaging due to the moisture-absorbing properties of the ingredients through continuous research, development, and improvement efforts. Both products were changed to tablets resistant to moisture, solving this problem.

Telmisartan is the most widely used ingredient in the hypertension treatment market. It blocks angiotensin II receptors, which constrict blood vessels and increase body fluid volume, thereby dilating blood vessels and reducing body fluid volume to lower blood pressure. Although it is a drug noted for its excellent blood pressure-lowering effect and long half-life, it had the drawback of requiring individual packaging to maintain stability due to its moisture-absorbing nature.

Daewoong Bio explained that the Telmisartan group’s renewal has a high effect on improving convenience, especially given the nature of hypertension treatments that require continuous use, and it has received positive responses particularly from patients taking multiple medications and elderly patients.

Jaeho Ko, PM at Daewoong Bio, said, "Telmisartan was vulnerable to moisture, which limited its convenience of use. The renewed product maintains stability even in bottle packaging through continuous research and formulation improvements, preserving the strengths of Telmisartan while increasing medication adherence and helping patients manage their blood pressure."

Currently, Daewoong Bio’s Telmisartan lineup includes the ARB+CCB combination drug 'Twinbeta', the single agent 'Telmibeta', and the ARB+diuretic combination drug 'Telmibeta Plus'. Additionally, a triple combination of ARB+CCB+diuretic is under development for personalized patient treatment. Through this, Daewoong Bio plans to further enhance the quality of life for hypertension patients.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.